EGFR and non-small cell lung carcinoma: In AURA3, a phase III trial investigating the efficacy and safety of osimertinib compared with platinum-pemetrexed among patients with EGFR T790M-positive locally advanced or metastatic NSCLC, the median PFS and OS were 10.1 and 26.8 months, respectively, in the osimertinib arm4,9.